← Back to Search

NMDA Receptor Antagonist

KAP for Depression in Abstinent Opioid Users (KReDO Trial)

Phase 2
Waitlist Available
Led By Eric T Dobson, MD
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at baseline, week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if ketamine shots combined with talking therapy can help people with past opioid addiction who are now depressed. Ketamine quickly changes brain activity to improve mood, while therapy helps manage emotions. Ketamine is used in treating multiple pain, mental health, and substance abuse disorders due to its rapid-acting pain relief and mood improvement effects.

Eligible Conditions
  • Depression
  • Addiction
  • Recovered from addiction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at baseline, week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at baseline, week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 16 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Montgomery Asberg Depression Rating Scale
Secondary study objectives
Beck Depression Inventory
Brief Pain Inventory (BPI)
Generalized Anxiety Disorder-7 (GAD-7)
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ketamine-assisted psychotherapyExperimental Treatment1 Intervention
Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.

Find a Location

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
979 Previous Clinical Trials
7,400,989 Total Patients Enrolled
44 Trials studying Depression
7,338 Patients Enrolled for Depression
Eric T Dobson, MDPrincipal InvestigatorMedical University of South Carolina
~1 spots leftby Dec 2025